| Notes |
Working with the World Health Organization, government, private-sector funders and organizations, and global regulatory and policy-setting institutions, the partners will share research, coordinate investments, and pool resources — from drug development through manufacturing and distribution. To identify candidate compounds, the initiative will take a three-pronged approach: testing approved drugs for their efficacy against COVID-19; screening libraries of thousands of compounds with confirmed safety data; and considering new investigational compounds and monoclonal antibodies. Drugs or monoclonal antibodies that pass initial screening will be developed by an industry partner. According to an accelerated timeline, it will take about a year to bring products with current regulatory approval — as well as candidates for which clinical data exist — to patients and longer for compounds further upstream in the drug development pipeline. |